Production of biopharmaceutical proteins by yeast: Advances through metabolic engineering

 Abstract

Production of recombinant proteins for use as pharmaceuticals, so-called biopharmaceuticals, is a multi-billion dollar industry. Many different cell factories are used for the production of biopharmaceuticals, but the yeast Saccharomyces cerevisiae is an important cell factory as it is used for production of several large volume products. Insulin and insulin analogs are by far the dominating biopharmaceuticals produced by yeast, and this will increase as the global insulin market is expected to grow from USD12B in 2011 to more than USD32B by 2018. Other important biopharmaceuticals produced by yeast are human serum albumin, hepatitis vaccines and virus like particles used for vaccination against human papillomavirus. Here is given a brief overview of biopharmaceutical production by yeast and it is discussed how the secretory pathway can be engineered to ensure more efficient protein production. The involvement of directed metabolic engineering through the integration of tools from genetic engineering, systems biology and mathematical modeling, is also discussed.

Full Text Options
Article
Metrics
 Share
 Full Text
 Info
Pages
207 - 211
doi
10.4161/bioe.22856
Type
Mini-Review
 Metrics
 Cite This Article
 Permissions
Creative Commons License Permissions
 Reprints
Production of biopharmaceutical proteins by yeast: Advances through metabolic engineering